{"id":4766,"date":"2024-10-08T13:32:33","date_gmt":"2024-10-08T11:32:33","guid":{"rendered":"https:\/\/avextra.com\/?p=4766"},"modified":"2024-10-08T13:56:27","modified_gmt":"2024-10-08T11:56:27","slug":"avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial","status":"publish","type":"post","link":"https:\/\/avextra.com\/it\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","title":{"rendered":"Avextra annuncia l\u2019approvazione da parte dell'Agenzia Italiana del Farmaco (AIFA) di NEUROBIS uno studio clinico di Fase II"},"content":{"rendered":"<p><strong>Bensheim, Germania, Oct. 08, 2024<\/strong> \u2013 Avextra AG (\"Avextra\" o la \"Societ\u00e0\"), un produttore e formulatore leader in Europa per i prodotti a base di cannabis con sede in Germania, \u00e8 orgogliosa di annunciare che sia l'Agenzia Italiana del Farmaco (AIFA) sia il Ministero della Salute hanno approvato ufficialmente  uno studio multicentrico di Fase II volto a valutare la sicurezza e l'efficacia di una formulazione orale sviluppata da Avextra per la gestione dei sintomi dei pazienti affetti da Sclerosi Laterale Amiotrofica (SLA), Malattia di Alzheimer e Malattia di Parkinson. Lo studio, condotto con l\u2019acronimo NEUROBIS, \u00e8 uno dei pochi studi randomizzati, controllati con placebo e in doppio cieco su un medicinale a base di cannabis condotti in Italia. Questo tipo di ricerca clinica \u00e8 perfettamente in linea con la vision di Avextra.<\/p>\n\n\n\n<p class=\"has-primary-color has-text-color\"><em><strong><a href=\"https:\/\/www.globenewswire.com\/en\/news-release\/2024\/10\/08\/2959537\/0\/en\/Avextra-Announces-the-Approval-of-NEUROBIS-by-the-Italian-Medicines-Agency-A-Phase-II-Clinical-Trial-Using-a-Proprietary-Cannabis-based-Medicine-for-the-Treatment-of-the-Symptoms-o.html\">Read mor<\/a><a href=\"https:\/\/www.globenewswire.com\/en\/news-release\/2024\/10\/08\/2959537\/0\/en\/Avextra-Announces-the-Approval-of-NEUROBIS-by-the-Italian-Medicines-Agency-A-Phase-II-Clinical-Trial-Using-a-Proprietary-Cannabis-based-Medicine-for-the-Treatment-of-the-Symptoms-o.html\" target=\"_blank\" rel=\"noreferrer noopener\">e<\/a><\/strong><\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Bensheim, Germania, Oct. 08, 2024 \u2014 Avextra AG<\/p>","protected":false},"author":2,"featured_media":4768,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"einzelbeitrag-ohne-bild","format":"standard","meta":{"inline_featured_image":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[9],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/avextra.com\/it\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra\" \/>\n<meta property=\"og:description\" content=\"Bensheim, Germany, Oct. 08, 2024 \u2014 Avextra AG\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/avextra.com\/it\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Cannabisbasierte Arzneimittel von Avextra\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-08T11:32:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-08T11:56:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Torsten Meyer-Bautor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Torsten Meyer-Bautor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\"},\"author\":{\"name\":\"Torsten Meyer-Bautor\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/aa74df4160383edd63d06428edfecd0b\"},\"headline\":\"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial\",\"datePublished\":\"2024-10-08T11:32:33+00:00\",\"dateModified\":\"2024-10-08T11:56:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\"},\"wordCount\":140,\"publisher\":{\"@id\":\"https:\/\/avextra.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\",\"articleSection\":[\"english\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\",\"url\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\",\"name\":\"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra\",\"isPartOf\":{\"@id\":\"https:\/\/avextra.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\",\"datePublished\":\"2024-10-08T11:32:33+00:00\",\"dateModified\":\"2024-10-08T11:56:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage\",\"url\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\",\"contentUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\",\"width\":1920,\"height\":1284},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/avextra.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/avextra.com\/#website\",\"url\":\"https:\/\/avextra.com\/\",\"name\":\"Cannabisbasierte Arzneimittel von Avextra\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/avextra.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/avextra.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/avextra.com\/#organization\",\"name\":\"Avextra Pharma GmbH\",\"url\":\"https:\/\/avextra.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg\",\"contentUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg\",\"caption\":\"Avextra Pharma GmbH\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/avextra-ag\/\",\"https:\/\/www.xing.com\/pages\/avextra\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/aa74df4160383edd63d06428edfecd0b\",\"name\":\"Torsten Meyer-Bautor\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b9ef8b21e6c420b5e45a3e65c39ed5b9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b9ef8b21e6c420b5e45a3e65c39ed5b9?s=96&d=mm&r=g\",\"caption\":\"Torsten Meyer-Bautor\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/avextra.com\/it\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","og_locale":"it_IT","og_type":"article","og_title":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra","og_description":"Bensheim, Germany, Oct. 08, 2024 \u2014 Avextra AG\u2026","og_url":"https:\/\/avextra.com\/it\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","og_site_name":"Cannabisbasierte Arzneimittel von Avextra","article_published_time":"2024-10-08T11:32:33+00:00","article_modified_time":"2024-10-08T11:56:27+00:00","og_image":[{"width":1920,"height":1284,"url":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","type":"image\/jpeg"}],"author":"Torsten Meyer-Bautor","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Torsten Meyer-Bautor","Tempo di lettura stimato":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/"},"author":{"name":"Torsten Meyer-Bautor","@id":"https:\/\/avextra.com\/#\/schema\/person\/aa74df4160383edd63d06428edfecd0b"},"headline":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial","datePublished":"2024-10-08T11:32:33+00:00","dateModified":"2024-10-08T11:56:27+00:00","mainEntityOfPage":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/"},"wordCount":140,"publisher":{"@id":"https:\/\/avextra.com\/#organization"},"image":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","articleSection":["english"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","url":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","name":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra","isPartOf":{"@id":"https:\/\/avextra.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","datePublished":"2024-10-08T11:32:33+00:00","dateModified":"2024-10-08T11:56:27+00:00","breadcrumb":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage","url":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","contentUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","width":1920,"height":1284},{"@type":"BreadcrumbList","@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/avextra.com\/"},{"@type":"ListItem","position":2,"name":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/avextra.com\/#website","url":"https:\/\/avextra.com\/","name":"Cannabisbasierte Arzneimittel von Avextra","description":"","publisher":{"@id":"https:\/\/avextra.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/avextra.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/avextra.com\/#organization","name":"Avextra Pharma GmbH","url":"https:\/\/avextra.com\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/avextra.com\/#\/schema\/logo\/image\/","url":"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg","contentUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg","caption":"Avextra Pharma GmbH"},"image":{"@id":"https:\/\/avextra.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/avextra-ag\/","https:\/\/www.xing.com\/pages\/avextra"]},{"@type":"Person","@id":"https:\/\/avextra.com\/#\/schema\/person\/aa74df4160383edd63d06428edfecd0b","name":"Torsten Meyer-Bautor","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/avextra.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b9ef8b21e6c420b5e45a3e65c39ed5b9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b9ef8b21e6c420b5e45a3e65c39ed5b9?s=96&d=mm&r=g","caption":"Torsten Meyer-Bautor"}}]}},"author_meta":{"display_name":"Torsten Meyer-Bautor","author_link":"https:\/\/avextra.com\/it\/author\/tmeyer-bautor\/"},"featured_img":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008-300x201.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/avextra.com\/it\/category\/english\/\" class=\"advgb-post-tax-term\">english<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">english<\/span>"]}},"comment_count":0,"relative_dates":{"created":"Pubblicato 2 anni fa","modified":"Aggiornato 2 anni fa"},"absolute_dates":{"created":"Pubblicato il 8. Ottobre 2024","modified":"Aggiornato il 8. Ottobre 2024"},"absolute_dates_time":{"created":"Pubblicato il 8. Ottobre 2024 13:32","modified":"Aggiornato il 8. Ottobre 2024 13:56"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/posts\/4766"}],"collection":[{"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/comments?post=4766"}],"version-history":[{"count":5,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/posts\/4766\/revisions"}],"predecessor-version":[{"id":4775,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/posts\/4766\/revisions\/4775"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/media\/4768"}],"wp:attachment":[{"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/media?parent=4766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/categories?post=4766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avextra.com\/it\/wp-json\/wp\/v2\/tags?post=4766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}